GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acurx Pharmaceuticals Inc (NAS:ACXP) » Definitions » PS Ratio

ACXP (Acurx Pharmaceuticals) PS Ratio : (As of Dec. 11, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Acurx Pharmaceuticals PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Acurx Pharmaceuticals's share price is $0.929. Acurx Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00. Hence, Acurx Pharmaceuticals's PS Ratio for today is .

The historical rank and industry rank for Acurx Pharmaceuticals's PS Ratio or its related term are showing as below:

ACXP's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 8.58
* Ranked among companies with meaningful PS Ratio only.

Acurx Pharmaceuticals's Revenue per Sharefor the three months ended in Sep. 2024 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00.

Back to Basics: PS Ratio


Acurx Pharmaceuticals PS Ratio Historical Data

The historical data trend for Acurx Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acurx Pharmaceuticals PS Ratio Chart

Acurx Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
- - - - -

Acurx Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Acurx Pharmaceuticals's PS Ratio

For the Biotechnology subindustry, Acurx Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acurx Pharmaceuticals's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acurx Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where Acurx Pharmaceuticals's PS Ratio falls into.



Acurx Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Acurx Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.929/0
=

Acurx Pharmaceuticals's Share Price of today is $0.929.
Acurx Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Acurx Pharmaceuticals  (NAS:ACXP) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Acurx Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of Acurx Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Acurx Pharmaceuticals Business Description

Traded in Other Exchanges
Address
259 Liberty Avenue, Staten Island, NY, USA, 10305
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
Executives
David P Luci director, 10 percent owner, officer: President and CEO
Robert J Deluccia director, 10 percent owner 40 WASHINGTON STREET, SUITE 220, WELLESLEY HILLS MA 02481
Carl Sailer director 4 GREENBRIAR LANE, MONTVALE NJ 07645
Thomas L Harrison director
Joseph C Scodari director JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Jack H Dean director C/O RESEARCH PHARMACEUTICAL SERVICES,INC, 520 VIRGINIA DRIVE, FORT WASHINGTON PA 19034
Robert G. Shawah officer: Chief Financial Officer C/O DIPEXIUM PHARMACEUTICALS, LLC, 74 BROAD STREET, NEW YORK NY 10004
James J. Donohue director C/O ACURX PHARMACEUTICALS, INC., 259 LIBERTY AVENUE, STATEN ISLAND NY 10305

Acurx Pharmaceuticals Headlines

From GuruFocus